Introduction
Chronic constipation is a very common medical problem. Depending on the definition, up to 15% of the general German population report symptoms of constipation, matching pooled prevalence rates of 14% across 18 other countries [1] . Prevalence rates are typically higher for women compared to men (2: 1) and increase with age. In the past, constipation was often solely defined by reduced stool frequency (e.g. <3 bowel movements/week). Modern definitions, such as the new Rome IV definition [2] (table 1) , recognize constipation as a polysymptomatic disorder including various aspects of disturbed defecation. A variety of primary and secondary disturbances of bowel functions (motility, secretion, sensitivity) or of defecation may lead to constipation. Quality of life may be substantially reduced in affected patients. On the other hand, patients may have to face prejudices that their constipation is just a simple lifestyle problem caused by 'wrong behavior' such as inadequate nutrition, insufficient fluid intake, and lack of physical activity. The establishment of medical guidelines and the development of new therapies may improve not only the treatment strategies but also the recognition of constipation as a relevant medical problem for many patients. The following article will cover current treatment standards and potential future treatment options.
Medical Therapy of Constipation

Baseline Measures Including Fiber
For the treatment of constipation, the German S2k consensus guideline recommends a stepwise approach ( fig. 1) [3] . Baseline management includes the evaluation and potential modification of lifestyle factors, such as nutritional fiber, fiber supplements, bulking agents, sufficient fluid intake, and regular, moderate physical activity. However, evidence levels for these measures are low, and while patients with mild or habitual constipation may experience
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Summary
Chronic constipation is a very common medical problem with relevant impact on the patients' quality of life. Modern definitions recognize constipation as a polysymptomatic disorder, including various aspects of disturbed defecation. Current guidelines recommend a stepwise approach in the management of chronic constipation. Isolated or concomitant evacuation disorders should be identified and may need differential/additional treatment. Baseline measures include lifestyle components and bulking agents. The next step recommends treatment with conventional laxatives. In refractory patients, modern medical therapies, such as the prokinetic prucalopride or the secretagogues linalotide or lubiprostone, may be used effectively. For patients with opioid-induced constipation, the modern concept of peripherally acting μ-opioid antagonists has shown to successfully improve this increasing medical problem and even to potentially increase survival time in terminally ill patients on opioid therapy. Prolonged-released oral naloxone (in fixed combination with oxycodone), oral naloxegol or naldemedine, and subcutaneous methylnaltrexone have all demonstrated good efficacy and tolerability in the treatment of opioid-induced constipation. To adequately apply stepwise treatment algorithms, a simple tool to identify treatment failure may improve patient care.
some symptom improvement, patients with more severe and chronic constipation rarely have notable beneficial effects.
To decide on further measures, it is important to identify a possible underlying evacuation disorder by a thorough history, a functional digital rectal examination, and, if indicated, further examinations, such as anorectal manometry, defecography, or balloon expulsion test. In patients with evacuation disorders, therapeutic measures to improve defecation, such as suppositories or enemas, biofeedback training in pelvic floor dyssynergia [4] , or even surgical measures in structural obstructions, such as rectoceles, should be considered ( fig. 1 ).
Laxatives
In patients with disturbed motility (and/or secretion), the next therapeutic step comprises conventional laxatives, for which efficacy has been demonstrated in several studies and meta-analyses [5] . Regarding osmotic laxatives, the best evidence of efficacy and safety -also for long-term treatment -is available for macrogol, while lactulose is less effective with more side effects, mainly bloating. Stimulant laxatives, such as natriumpicosulfate or bisacodyl, have also proven to be effective and safe in randomized clinical trials, while anthrachinones would only be second choice due to lower quality evidence. Recent studies underline the overall safety of laxative treatment even in elderly patients [6, 7] , while the potential risk of major side effects, such as dehydration and electrolyte disturbance, appears to be overestimated as long as laxatives are used correctly and with the aim to normalize bowel function without inducing diarrhea.
In the light of the different mechanisms of action, a combination of osmotic and stimulant laxatives or a combination of laxatives with bulking agents may be considered in refractory patients.
Prokinetics and Secretagogues
In patients with inadequate response to or poor tolerance of conventional laxative treatment, modern medical therapies are indicated.
The prokinetic agent prucalopride acts as a selective agonist of the 5-HT4-receptor and thereby stimulates gastrointestinal motility. Several large phase III trials and meta-analyses have demonstrated a good efficacy of prucalopride in patients with severe, laxative-refractory constipation [8] [9] [10] [11] [12] . Significant endpoints included normalization of stool frequency as well as improvement of various constipation symptoms and quality of life [13] . Potential adverse effects -especially at the initiation of therapy -include headache, nausea, and diarrhea. In contrast to previous 5-HT4-agonistic agents, such as cisapride or tegaserod, the highly selective prucalopride has not been associated with any cardiac side effects [14] . The Table 1 . Diagnostic criteria for functional constipation [2] 1. Must include two or more of the following: a. Straining during more than one-fourth (25%) of defecations b. Lumpy or hard stools (BSFS 1"2) more than one-fourth (25%) of defecations c. Sensation of incomplete evacuation more than one-fourth (25%) of defecations d. Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations e. Manual maneuvers to facilitate more than one fourth (25%) of defecations (e.g., digital evacuation, support of the pelvic floor) f. Fewer than 3 spontaneous bowel movements per week 2. Loose stools are rarely present without the use of laxatives 3. Insufficient criteria for irritable bowel syndrome a Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis. initial European Medicines Agency (EMA) approval only covered female patients because the pivotal trials included only few men. Hence, an additional 'only-male' phase III trial was added including 370 men with severe constipation. The primary endpoint, defined as 3 complete spontaneous bowel movements/week during a 12-week period, was reached by 38% of patients taking prucalopride compared to 18% in the placebo group (p < 0.0001) ( fig. 2 ) [15] .
The positive results of this study led to an extended EMA approval for both women and men with constipation failing prior laxative treatment.
The trial evidence also supports effective and safe long-term treatment of chronic constipation with prucalopride [16] .
Other 5-HT4-agonistic compounds, such as velusetrag or naronapride, have also been developed for the treatment of gastrointestinal motility disorders and have proved efficacy in chronic constipation [17] .
Secretagogues
Linaclotide is the first-in-class selective guanylate cyclase C (GC-C) agonist with secretory and visceral antinociceptive properties. It binds locally to GC-C receptors on the surface of intestinal epithelial cells and thereby induces intracellular cyclic GMP (cGMP). On the one hand, this leads to activation of the cystic fibrosis transmembrane conductance regulator (CFTR) with stimulation of water, bicarbonate, and electrolyte secretion into the intestinal lumen, leading to soft stool consistency and increased stool frequency [18] . On the other hand, linaclotide has also been shown to reduce visceral pain, possibly also mediated by cGMP [19] .
Linaclotide has been evaluated in a large clinical trial program both for chronic constipation (at a dose of 145 μg) and for constipation-predominant irritable bowel syndrome (IBS-C) (at a dose of 290 μg), demonstrating significant and clinically relevant efficacy in improving both the broad variety of constipation symptoms as well as abdominal pain and bloating [20] [21] [22] [23] [24] (fig. 3 ). Diarrhea has been detected as the only relevant adverse effect leading to treatment cessation in some of the patients. Since the incidence of diarrhea is dose-related, a lower dose of linaclotide (72 μg) has been developed and marketed in the USA. In Europe, however, linaclotide is only licensed for IBS-C and is only available at a dose of 290 μg.
In Germany, linaclotide marketing was stopped for a while due to reimbursement issues, but it has recently been reintroduced in a large packaging size (112 capsules/package). Smaller packaging sizes for new treatment initiations may be imported from other European countries via international pharmacy.
Another GC-C agonist, plecanatide, has demonstrated a similar efficacy and safety as linaclotide [25, 26] and has recently been approved by the Food and Drug Administration (FDA) for the treatment of chronic constipation and IBS-C in the USA.
Lubiprostone is a chloride channel activator approved in the USA, in the UK, and in Switzerland for chronic constipation, and for IBS-C (in the USA only). Its mode of action involves induction of water and chloride secretion into the intestinal lumen, leading in turn to decreased stool consistency as well as increased stool volumes and stool transit velocity. Lubiprostone has been shown to be clearly more effective than placebo in several studies and meta-analyses [27] , and has been associated with reports of possible adverse effects including diarrhea, nausea, and abdominal cramps. Peripherally Acting μ-Opioid Antagonists (PAMORA) for Opioid-Induced Constipation Opioids play a significant role in the management of chronic pain. Their mode of action is based on activation of central nervous μ-opioid receptors but also involves activation of μ-opioid receptors in peripheral structures. These latter effects in turn are the cause for most classical opioid-associated side effects, the most important of which is opioid-induced constipation (OIC). This is a clinically highly relevant problem compromising opioid therapy, and is explained by the crucial role of opioid receptors in the enteric neural regulation of intestinal motility and secretion.
As a result, patients may experience greater loss of quality of life by severe OIC than by their underlying pain. This difficult clinical challenge is exacerbated by the observation that the efficacy of conventional laxatives is often limited in OIC therapy.
Modern treatment concepts therefore aim to target the underlying pathomechanism of OIC by selectively blocking the opioid effects on intestinal μ-opioid receptors and thus reduce/prevent gastrointestinal side effects without disturbing central (analgetic) effects of opioids [28] .
One option is the oral prolonged-release (PR) form of naloxone. Naloxone is a systemic opioid antagonist; however, in oral application, its main action is limited to the intestinal μ-receptors due to a high first-pass-effect in the liver. PR-naloxone is currently available in a fixed-combination tablet with the opioid pain agent oxycodone. This fixed-combination has proven efficacy in pain therapy with concomitant reduction/prevention of OIC [29] . Shortcomings of this approach include the inherent rigidity with regard to application of substances, routes of administration, and dosages, as well as the need for adequate liver function to prevent systemic exposure of naloxone.
The introduction of true peripherally acting μ-opioid antagonists (PAMORA), which do not pass the blood-brain barrier, has therefore significantly enriched the treatment options of OIC, as they can be combined with all types and administration routes of opioid pain medication.
In Europe, currently available PAMORAs are naloxegol, an oral tablet, and methylnaltrexone as subcutaneous application (in the USA also licensed as an oral preparation). In phase III studies, both substances have been shown to be highly effective and tolerable [30] [31] [32] ; both drugs may be combined with all available opioid regimes irrespective of the choices of substance, medication routes, or dosing.
A new oral PAMORA, naldemedine, which has also demonstrated good efficacy and tolerability in a large clinical trial program [33] [34] [35] , has recently been approved by the FDA and is currently undergoing licensing application at the EMA.
Introduction of PAMORAs into the treatment armamentarium of chronic pain syndromes has shown to be a major advance, as they eliminate or substantially mitigate OIC as the most frequent and most relevant side effect of chronic opioid therapy. Moreover, it has been shown that effective treatment of OIC may prolong survival in opioid-treated cancer patients [36] .
Assessment of Treatment Failure
Chronic constipation is managed in many cases by the patients themselves or in primary care; however, rates of objective treatment success and subjective patient satisfaction with treatment outcomes are low, and patients with unresponsive symptoms should be referred to secondary care. To support and ensure this referral process and to initiate more intensive medical therapy as recommended by treatment algorithms [3] , it is necessary to determine criteria for inadequate constipation relief. Such criteria have been proposed by a recent international expert consensus [37] addressing this important issue (table 2) .
As it is crucial for effective management of chronic constipation to discern, and respond to, evidence of inadequate therapeutic relief, this compilation may provide a workable definition of treatment failure, and should be useful in clinical practice to evaluate (the extent of) therapeutic success. Moreover, it may be used as a standardizing calibration tool in the context of clinical trials [37] .
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Speaker and/or consulting fees: VA: Allergan, Boehringer Ingelheim, Ferring, KyowaKirin, Nordmark, Shionogi; PL: Allergan, Abbott, Abbvie, Falk, Ardeypharm, Nordmark, Norgine. Table 2 . Criteria of treatment failure of constipation [37] Failure to provide adequate relief may be assumed if any 1 of the following 5 statements applies to the patient during the last 1 or 2 weeks: • Inadequate number of bowel movements reported by the patient most of the time and complete bowel movements <3 days per week.
• Need to strain on most occasions (or straining is getting worse) • No improvement a in stool consistency on current therapy and the Bristol Stool Scale score is less than 3 (hard and lumpy or very hard and small) • Insufficient improvement a of other signs and/or symptoms of chronic constipation on current treatment.
• Poor tolerability of current treatment makes the relief provided unacceptable.
a The terms 'no or insufficient improvement' includes 'worsening'.
